SLC5A2 and acute kidney injury: For other safety outcomes, the risks of graft rejection (OR: 0.73 and 95% CI: 0.64–0.83) (Figure 2e) and all‐cause mortality (OR: 0.40 and 95% CI: 0.27–0.59) (Figure 2g) were significantly lower in the SGLT2 inhibitor group, whereas the risk of AKI showed no significant difference between the two groups.